Gynecological Contraceptive Implants are long-acting, reversible contraceptive devices, typically inserted subcutaneously or in the uterus, offering reliable birth control for women. These implants, available as non-biodegradable and biodegradable types, are critical for family planning and reproductive health. The market is characterized by its role in women’s healthcare, driven by rising awareness of contraception, increasing demand for minimally invasive solutions, and supportive government policies. Trends include smart implants with remote monitoring, biodegradable materials, and expanded access in developing regions.
AbbVie, headquartered in North Chicago, Illinois, USA, provides implants for women’s health, emphasizing efficacy. AbbVie invests in biodegradable materials and is targeting Asia for growth.
CooperSurgical, based in Trumbull, Connecticut, USA, offers Paragard IUD with a new single-hand inserter launched in 2024, enhancing ease of use. The company is growing in Europe with smart implants.
Egemen International, from Izmir, Turkey, supplies affordable implants for Middle Eastern markets, supporting family planning. Egemen is developing biodegradable implants and targeting Africa.
ERENLER MEDIKAL, based in Istanbul, Turkey, provides cost-effective implants for regional hospitals, focusing on durability. ERENLER is integrating smart features and expanding in Asia.
Gyneas, headquartered in Goussainville, France, offers uterine implants for European clinics, emphasizing patient comfort. Gyneas is developing eco-friendly designs and targeting Latin America.
Laboratoire CCD, from Paris, France, supplies implants for women’s health, known for precision. CCD invests in biodegradable materials and is growing in the Middle East.
Medical Engineering Corporation, based in Tokyo, Japan, provides implants for Asian markets, focusing on affordability. The company is developing smart implants and targeting Southeast Asia.
Melbea, headquartered in Warsaw, Poland, offers implants for European hospitals, emphasizing ease of insertion. Melbea is integrating digital monitoring and targeting Africa.
Meril Life Sciences, from Vapi, India, supplies affordable implants for Indian clinics, supporting family planning. Meril is developing biodegradable implants and targeting Latin America.
Mona Lisa, based in Genk, Belgium, provides uterine implants for European markets, focusing on efficacy. Mona Lisa is investing in smart technology and expanding in Asia.
Pregna International, headquartered in Mumbai, India, offers cost-effective implants for developing regions, known for accessibility. Pregna is developing eco-friendly designs and targeting Africa.
Prosan International, from Arnhem, Netherlands, supplies implants for European clinics, emphasizing patient safety. Prosan is integrating smart features and targeting the Middle East.
Rongbo Medical, based in Weihai, China, provides affordable implants for Asian hospitals, supporting rural healthcare. Rongbo is developing biodegradable implants and targeting Europe.
SMB Corporation of India, from Mumbai, India, offers cost-effective implants for Indian markets, focusing on quality. SMB is integrating smart technology and targeting Africa.
Pregna, headquartered in Mumbai, India, supplies implants for global family planning, emphasizing affordability. Pregna is developing eco-friendly implants and targeting Latin America.
This product will be delivered within 1-3 business days.
Market Size and Growth Forecast
The global Gynecological Contraceptive Implant market was valued at USD 0.7-1.2 billion in 2024, with an estimated CAGR of 5.0%-7.0% from 2025 to 2030, fueled by reproductive health initiatives and technological advancements.Regional Analysis
- North America grows at 4.5%-6.5%; the U.S. leads due to high healthcare access, with trends focusing on smart implants.
- Europe achieves 4.8%-6.8% growth; Germany and France drive demand through robust healthcare systems, emphasizing biodegradable implants.
- Asia Pacific records 5.5%-7.5% growth; India and China are key markets, with trends toward affordable implants and government-backed family planning.
- Rest of the World grows at 4.5%-6.5%; Brazil and South Africa show potential, with trends centering on rural healthcare access.
Application Analysis
- Subcutaneously expands at 5.0%-7.0%; it offers long-term contraception, with trends favoring smart monitoring systems.
- Uterus grows at 5.3%-7.3%; it provides high efficacy, emphasizing biodegradable materials.
Type Analysis
- Non-biodegradable expands at 4.8%-6.8%; it ensures long-term reliability, with trends focusing on user-friendly designs.
- Biodegradable grows at 5.5%-7.5%; it reduces removal procedures, emphasizing eco-friendly materials.
Key Market Players
Bayer, based in Leverkusen, Germany, is a leader in contraceptive implants, offering products like Nexplanon for subcutaneous use. Bayer focuses on patient education and is expanding in Africa to enhance access.AbbVie, headquartered in North Chicago, Illinois, USA, provides implants for women’s health, emphasizing efficacy. AbbVie invests in biodegradable materials and is targeting Asia for growth.
CooperSurgical, based in Trumbull, Connecticut, USA, offers Paragard IUD with a new single-hand inserter launched in 2024, enhancing ease of use. The company is growing in Europe with smart implants.
Egemen International, from Izmir, Turkey, supplies affordable implants for Middle Eastern markets, supporting family planning. Egemen is developing biodegradable implants and targeting Africa.
ERENLER MEDIKAL, based in Istanbul, Turkey, provides cost-effective implants for regional hospitals, focusing on durability. ERENLER is integrating smart features and expanding in Asia.
Gyneas, headquartered in Goussainville, France, offers uterine implants for European clinics, emphasizing patient comfort. Gyneas is developing eco-friendly designs and targeting Latin America.
Laboratoire CCD, from Paris, France, supplies implants for women’s health, known for precision. CCD invests in biodegradable materials and is growing in the Middle East.
Medical Engineering Corporation, based in Tokyo, Japan, provides implants for Asian markets, focusing on affordability. The company is developing smart implants and targeting Southeast Asia.
Melbea, headquartered in Warsaw, Poland, offers implants for European hospitals, emphasizing ease of insertion. Melbea is integrating digital monitoring and targeting Africa.
Meril Life Sciences, from Vapi, India, supplies affordable implants for Indian clinics, supporting family planning. Meril is developing biodegradable implants and targeting Latin America.
Mona Lisa, based in Genk, Belgium, provides uterine implants for European markets, focusing on efficacy. Mona Lisa is investing in smart technology and expanding in Asia.
Pregna International, headquartered in Mumbai, India, offers cost-effective implants for developing regions, known for accessibility. Pregna is developing eco-friendly designs and targeting Africa.
Prosan International, from Arnhem, Netherlands, supplies implants for European clinics, emphasizing patient safety. Prosan is integrating smart features and targeting the Middle East.
Rongbo Medical, based in Weihai, China, provides affordable implants for Asian hospitals, supporting rural healthcare. Rongbo is developing biodegradable implants and targeting Europe.
SMB Corporation of India, from Mumbai, India, offers cost-effective implants for Indian markets, focusing on quality. SMB is integrating smart technology and targeting Africa.
Pregna, headquartered in Mumbai, India, supplies implants for global family planning, emphasizing affordability. Pregna is developing eco-friendly implants and targeting Latin America.
Porter’s Five Forces Analysis
- The threat of new entrants is moderate; high regulatory barriers deter entry, but demand attracts niche players.
- The threat of substitutes is moderate; alternative contraceptives compete, but implants’ long-term efficacy retains preference.
- Buyer power is moderate; healthcare providers demand reliable products, but large systems can negotiate pricing.
- Supplier power is low; materials like hormones and polymers are widely available, reducing supplier leverage.
- Competitive rivalry is high; firms differentiate through smart technology, biodegradability, and affordability.
Market Opportunities and Challenges
Opportunities
- Rising family planning initiatives drive demand for contraceptive implants.
- Smart and biodegradable implants enhance patient outcomes and market growth.
- Emerging markets offer expansion as healthcare access improves in Africa and Asia.
Challenges
- High costs of advanced implants limit adoption in low-resource regions.
- Regulatory scrutiny on safety increases production costs.
- Cultural barriers in some regions hinder implant acceptance.
Growth Trend Analysis
The Gynecological Contraceptive Implant market is growing steadily, driven by increasing reproductive health awareness and technological advancements. CooperSurgical’s launch of Paragard IUD with a new single-hand inserter in 2024 enhances ease of use, driving adoption in clinical settings. Sebela Women’s Health’s publication of Phase 3 results for the Copper 175 mm² IUD in 2024 underscores innovation in uterine implants, boosting market confidence. The market aligns with a projected CAGR of 5.0%-7.0% through 2030, supported by global family planning initiatives and healthcare access expansion.This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Trading Analysis
Chapter 9 Historical and Forecast Gynecological Contraceptive Implant Market in North America (2020-2030)
Chapter 10 Historical and Forecast Gynecological Contraceptive Implant Market in South America (2020-2030)
Chapter 11 Historical and Forecast Gynecological Contraceptive Implant Market in Asia & Pacific (2020-2030)
Chapter 12 Historical and Forecast Gynecological Contraceptive Implant Market in Europe (2020-2030)
Chapter 13 Historical and Forecast Gynecological Contraceptive Implant Market in MEA (2020-2030)
Chapter 14 Summary For Global Gynecological Contraceptive Implant Market (2020-2025)
Chapter 15 Global Gynecological Contraceptive Implant Market Forecast (2025-2030)
Chapter 16 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- Bayer
- AbbVie
- CooperSurgical
- Egemen International
- ERENLER MEDIKAL
- Gyneas
- Laboratoire CCD
- Medical Engineering Corporation
- Melbea
- Meril Life Sciences
- Mona Lisa
- Pregna International
- Prosan International
- Rongbo Medical
- SMB Corporation of India
- Pregna
